Previous Article | Next Article ![]()
Journal of Clinical Microbiology, January 2005, p. 208-213, Vol. 43, No. 1
0095-1137/05/$08.00+0 doi:10.1128/JCM.43.1.208-213.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.
Division of Infectious Diseases,1 Pediatric Infectious Diseases, University of Colorado Health Sciences Center,4 The Children's Hospital, Denver, Colorado,3 VA Medical Center and Oregon Health Sciences University, Portland, Oregon2
Received 9 June 2004/ Returned for modification 27 August 2004/ Accepted 10 September 2004
Infection with cytomegalovirus (CMV) remains a significant cause of morbidity and mortality among hematopoietic cell transplant (HCT) recipients. We describe two pediatric HCT recipients who developed persistent and severe drug-resistant CMV infections. CMV resistance to foscarnet and ganciclovir was detected after only 6 and 11 weeks of therapy, respectively. Viral pol mutations associated with drug resistance in these patients included T838A (a novel mutation) and D588N, which were shown by marker transfer to confer foscarnet and multidrug resistance, respectively. Each of these mutations significantly reduced in vitro replication of CMV, suggesting that they may decrease viral fitness. This finding was further supported by the disappearance of mutations upon withdrawal of antiviral pressure in one patient. Novel antivirals or combination therapy may be required for the treatment of drug-resistant CMV in HCT recipients and perhaps in other severely immunocompromised patients.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»